Evidence map›Paper›PMID 36555579›Full record

ReviewInternational journal of molecular sciences2022

The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches.

Panagiotis Tsioufis, Panagiotis Theofilis, Konstantinos Tsioufis, Dimitris Tousoulis

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 2 pooled it
5.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Cocktail-style multifunctional resuscitation fluids: Where are we now in 2026?Journal of anesthesia and translational medicine · 2026
    Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Panagiotis TsioufisFirst Department of Cardiology, "Hippokration" General Hospital, University of Athens Medical School, 11527 Athens, Greece.ORCID 0000-0002-1100-7430
Panagiotis TheofilisFirst Department of Cardiology, "Hippokration" General Hospital, University of Athens Medical School, 11527 Athens, Greece.ORCID 0000-0001-9260-6306
Konstantinos TsioufisFirst Department of Cardiology, "Hippokration" General Hospital, University of Athens Medical School, 11527 Athens, Greece.
Dimitris TousoulisFirst Department of Cardiology, "Hippokration" General Hospital, University of Athens Medical School, 11527 Athens, Greece.
National and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronary atherosclerosis is a chronic pathological process that involves inflammation together with endothelial dysfunction and lipoprotein dysregulation. Experimental studies during the past decades have established the role of inflammatory cytokines in coronary artery disease, namely interleukins (ILs), tumor necrosis factor (TNF)-α, interferon-γ, and chemokines. Moreover, their value as biomarkers in disease development and progression further enhance the validity of this interaction. Recently, cytokine-targeted treatment approaches have emerged as potential tools in the management of atherosclerotic disease. IL-1β, based on the results of the CANTOS trial, remains the most validated option in reducing the residual cardiovascular risk. Along the same line, colchicine was also proven efficacious in preventing major adverse cardiovascular events in large clinical trials of patients with acute and chronic coronary syndrome. Other commercially available agents targeting IL-6 (tocilizumab), TNF-α (etanercept, adalimumab, infliximab), or IL-1 receptor antagonist (anakinra) have mostly been assessed in the setting of other inflammatory diseases and further testing in atherosclerosis is required. In the future, potential targeting of the NLRP3 inflammasome, anti-inflammatory IL-10, or atherogenic chemokines could represent appealing options, provided that patient safety is proven to be of no concern.

Indexed as

AtherosclerosisCoronary Artery DiseasePlaque, AtheroscleroticAnti-Inflammatory AgentsCytokinesHumansInflammationTumor Necrosis Factor-alphaAnti-Inflammatory AgentsCytokinesTumor Necrosis Factor-alphaatherosclerosiscoronary artery diseaseinflammationinterleukintumor necrosis factor

Identifiers

PMID36555579
PMCPMC9788180
OpenAlexW4312212048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.